Your browser is no longer supported. Please, upgrade your browser.
SGMO [NASD]
Sangamo Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.95 Insider Own0.30% Shs Outstand143.98M Perf Week6.50%
Market Cap1.38B Forward P/E- EPS next Y-1.36 Insider Trans-3.99% Shs Float120.33M Perf Month0.20%
Income-135.30M PEG- EPS next Q-0.34 Inst Own53.80% Short Float9.48% Perf Quarter-16.69%
Sales137.70M P/S10.03 EPS this Y-6.00% Inst Trans-3.99% Short Ratio12.03 Perf Half Y-19.89%
Book/sh3.09 P/B3.18 EPS next Y-3.00% ROA-15.00% Target Price- Perf Year-0.61%
Cash/sh3.77 P/C2.61 EPS next 5Y- ROE-28.00% 52W Range8.90 - 19.43 Perf YTD-37.01%
Dividend- P/FCF- EPS past 5Y-9.10% ROI-26.10% 52W High-50.23% Beta1.67
Dividend %- Quick Ratio4.00 Sales past 5Y24.50% Gross Margin- 52W Low8.65% ATR0.39
Employees413 Current Ratio4.00 Sales Q/Q29.20% Oper. Margin- RSI (14)49.48 Volatility3.53% 3.89%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.70% Profit Margin-98.20% Rel Volume0.43 Prev Close9.83
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume948.62K Price9.67
Recom2.10 SMA20-0.51% SMA50-1.02% SMA200-18.46% Volume321,750 Change-1.63%
May-04-21Initiated RBC Capital Mkts Outperform $22
Jan-07-21Resumed Guggenheim Neutral $16
Jan-06-21Initiated Stifel Hold $16
Dec-16-20Resumed H.C. Wainwright Buy $25
Sep-08-20Initiated BofA Securities Buy $20
Jul-07-20Initiated SunTrust Buy $22
Aug-26-19Initiated H.C. Wainwright Buy $16
Nov-14-18Downgrade JP Morgan Overweight → Neutral
Nov-09-18Downgrade Guggenheim Buy → Neutral
Oct-10-18Initiated Guggenheim Buy
Jun-20-18Initiated BofA/Merrill Buy $24
Nov-15-17Upgrade Piper Jaffray Neutral → Overweight
Jun-22-17Resumed Jefferies Buy $17
Nov-01-16Downgrade Wedbush Outperform → Neutral $30 → $4
Oct-19-16Downgrade Piper Jaffray Overweight → Neutral
Dec-04-15Initiated Wells Fargo Outperform
Oct-23-15Resumed Jefferies Buy
May-03-13Initiated BioLogic Equity Research Sell
Feb-23-11Reiterated JMP Securities Mkt Outperform $9 → $12
Jul-29-10Reiterated Wedbush Outperform $12 → $13
Aug-31-21 08:30AM  
Aug-10-21 05:21AM  
Aug-09-21 04:30PM  
Aug-05-21 05:45PM  
04:01PM  
Jul-30-21 12:15PM  
Jul-29-21 04:30PM  
Jul-28-21 03:03PM  
Jun-14-21 11:51AM  
Jun-07-21 10:22AM  
May-24-21 04:15PM  
May-21-21 08:30AM  
May-12-21 01:52PM  
May-05-21 05:01AM  
May-04-21 05:25PM  
04:01PM  
03:15PM  
May-03-21 04:30PM  
Apr-27-21 04:30PM  
04:15PM  
Mar-25-21 08:30AM  
Mar-17-21 04:30PM  
Mar-16-21 03:26PM  
Mar-09-21 05:10AM  
Mar-01-21 11:10AM  
Feb-26-21 09:34AM  
Feb-25-21 06:30PM  
Feb-24-21 04:01PM  
03:15PM  
Feb-18-21 04:15PM  
Feb-17-21 04:15PM  
Feb-01-21 04:05PM  
Jan-07-21 11:25PM  
Jan-06-21 04:10PM  
Jan-05-21 08:00AM  
Dec-15-20 10:54AM  
10:40AM  
Dec-14-20 08:43AM  
Dec-10-20 02:03PM  
Dec-07-20 07:00AM  
Nov-30-20 06:42AM  
Nov-24-20 11:39AM  
Nov-05-20 08:00AM  
Nov-04-20 11:02PM  
05:45PM  
04:01PM  
03:15PM  
Oct-28-20 04:15PM  
12:32PM  
Oct-16-20 11:36AM  
Oct-07-20 06:45AM  
Oct-05-20 11:41AM  
Sep-28-20 08:30AM  
Sep-15-20 10:48AM  
Sep-11-20 08:30AM  
Sep-10-20 12:11PM  
Sep-02-20 04:15PM  
Sep-01-20 03:47PM  
Aug-20-20 09:43AM  
Aug-19-20 12:19PM  
Aug-10-20 08:30AM  
Aug-05-20 06:35PM  
04:01PM  
Aug-03-20 12:49PM  
Jul-30-20 07:00AM  
Jul-29-20 04:15PM  
12:33PM  
Jul-27-20 06:07PM  
Jul-09-20 07:43AM  
07:31AM  
Jun-24-20 08:00AM  
Jun-19-20 12:22PM  
Jun-18-20 09:44AM  
09:01AM  
09:00AM  
Jun-16-20 08:36AM  
Jun-15-20 10:40PM  
Jun-14-20 06:00AM  
Jun-11-20 05:14PM  
May-29-20 09:00AM  
May-12-20 09:15AM  
01:01AM  
May-11-20 05:15PM  
04:01PM  
May-07-20 05:15PM  
May-05-20 11:30AM  
May-04-20 04:15PM  
Apr-29-20 07:14AM  
Apr-28-20 04:30PM  
Apr-21-20 07:00AM  
Apr-19-20 08:09AM  
Apr-17-20 08:30AM  
Apr-09-20 08:00AM  
Mar-09-20 01:37PM  
Mar-06-20 05:39AM  
Mar-05-20 08:27AM  
Mar-04-20 09:55AM  
Mar-02-20 08:30AM  
Feb-28-20 04:48PM  
11:08AM  
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LOEB GARYEVP, General Counsel & Sec.Mar 23Option Exercise11.0211,981132,031100,762Mar 25 07:19 PM
LOEB GARYEVP, General Counsel & Sec.Mar 23Sale13.1317,524230,04283,238Mar 25 07:19 PM
Ramelmeier Rolf AndrewEVP, Technical OperationsDec 31Sale16.742,46441,24765,978Jan 06 04:27 PM
Ramelmeier Rolf AndrewEVP, Technical OperationsDec 24Sale18.133,33160,39168,442Dec 30 07:51 PM
Ramasastry SairaDirectorDec 17Option Exercise5.9910,00059,90025,000Dec 18 07:18 PM
Ramasastry SairaDirectorDec 17Sale13.2710,000132,74715,000Dec 18 07:18 PM